Astrana Health (NASDAQ:ASTH) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of Astrana Health (NASDAQ:ASTH) from a hold rating to a strong sell rating in a research note released on Monday morning,Zacks.com reports.

Several other research analysts have also weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Astrana Health in a research report on Wednesday, October 8th. BTIG Research lowered their target price on Astrana Health from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, TD Cowen reduced their price objective on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Monday. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.29.

Astrana Health Stock Up 6.1%

Shares of NASDAQ:ASTH opened at $23.80 on Monday. The firm has a market cap of $1.33 billion, a P/E ratio of 46.67, a P/E/G ratio of 0.90 and a beta of 0.79. Astrana Health has a 12-month low of $21.20 and a 12-month high of $46.74. The business has a fifty day simple moving average of $30.09 and a 200 day simple moving average of $27.78. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.52.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Wednesday, January 10th. The company reported $0.50 earnings per share (EPS) for the quarter. Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.The company had revenue of $317.00 million during the quarter. Analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ASTH. Principal Financial Group Inc. raised its position in Astrana Health by 2.3% in the 1st quarter. Principal Financial Group Inc. now owns 221,896 shares of the company’s stock valued at $6,881,000 after buying an additional 4,963 shares during the last quarter. Hussman Strategic Advisors Inc. boosted its holdings in Astrana Health by 33.3% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the company’s stock worth $2,605,000 after acquiring an additional 21,000 shares during the last quarter. Allianz Asset Management GmbH grew its stake in shares of Astrana Health by 32.5% in the 1st quarter. Allianz Asset Management GmbH now owns 32,600 shares of the company’s stock worth $1,011,000 after acquiring an additional 8,000 shares in the last quarter. Diamond Hill Capital Management Inc. raised its holdings in shares of Astrana Health by 32.6% in the first quarter. Diamond Hill Capital Management Inc. now owns 211,038 shares of the company’s stock valued at $6,544,000 after purchasing an additional 51,827 shares during the last quarter. Finally, Royce & Associates LP lifted its position in shares of Astrana Health by 13.8% during the first quarter. Royce & Associates LP now owns 290,707 shares of the company’s stock valued at $9,015,000 after purchasing an additional 35,155 shares in the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.